[Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
The prognosis in cases of advanced lung cancer with poor performance status is poor. We report here a patient with advanced non-small cell lung cancer of performance status 3 who had severe cancer-induced pain, which was not controlable with morphine and radiation therapy. The cancer was successfully treated by oral administration of gefitinib (250 mg/day) without serious adverse effects of worsening of quality of life. Not only was the tumor controlled but rapid relief of severe cancer-induced pain was achieved.
Kambayashi
Takatoyo
T
Dept. of Surgery, Kyoto Min-iren, The Second Center Hospital.
Ishibashi
Osamu
O
Yanagihara
Kazuhiro
K
Tanaka
Fumiaki
F
Hasegawa
Seiki
S
Wada
Hiromi
H
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010148:Intractable Pain / Q000628:therapy; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib